Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Statement

5 Jul 2011 07:00

RNS Number : 7521J
Persimmon PLC
05 July 2011
 



TRADING UPDATE

 

TUESDAY 5 JULY 2011

 

 

Persimmon plc announces the following update ahead of its Half Year Results to 30 June 2011, which will be released on Tuesday 23 August 2011.

 

Market conditions during the first half of the year have been stable allowing the business to focus on delivering improved operating margins, generating good levels of free cash flow and successfully securing residential consents on a number of strategic land parcels.

 

During the first six months of 2011 we have legally completed 4,439 homes (2010: 4,657) with sales improving from the lower sales order book at the start of the year. As previously indicated we anticipate delivering a similar number of legal completions this year as in 2010, with an increase in volume in the second half over the prior year. Turnover for the first six months was c. £715 million. Sales rates continued to improve through the spring selling season. Since our Interim Management Statement in April the value of our private sales reservations is 6% higher than the same period last year. Our order book at 30 June 2011 is now ahead of the same point last year with forward sales at c. £725 million. This places us in a strong position for the second half.

 

We are currently selling new homes from c. 380 sites and healthy visitor levels demonstrate that underlying demand is resilient. We have successfully opened 70 new sites in the first half of the year and have identified a further c. 70 sites for sales release during the second half. Cancellation rates continue to run at a low level of c. 17%.

 

Underlying pricing remains firm for the year to date. Average selling price for the first half of the year was c. £162,000 (2010: £168,936) reflecting the legal completion of a greater proportion of smaller house types in the period. However, we anticipate that our average selling price for the full year will increase as we legally complete more detached house sales already included in our forward order book.

 

We anticipate underlying operating margins for the first half, before exceptional items and goodwill charges, will show further improvement to c. 9.0% (H1 2010: 8.0%).

 

Any meaningful increase in industry output will only occur with a significant improvement in the currently constrained mortgage lending conditions. We continue to see some modest improvement in mortgage lending with a greater number of higher loan to value products available in the market. We have been successful in securing c. £35 million of funding from the Government under their FirstBuy Scheme to support first time buyers in the market. We look forward to introducing this facility to our customers across the c. 290 sites where c. 2,100 new homes have been allocated support. Our customers have also been keen to take advantage of our part exchange facilities which provide a very convenient method for acquiring a newly built home.

 

We continue to invest in high quality land, which will support both the improvement in the Company's profitability over the medium term and an expansion in legal completions as and when market conditions allow. During the last six months we have acquired c. 7,500 plots of land, c. 36% of which have been secured through successfully converting strategic land positions. Notable successes have been c. 800 plots at Gatwick in the South East and c. 200 plots at Whinmoor in Leeds, West Yorkshire. These anchor sites will deliver superior returns for the business in the coming years.

 

At 30 June 2011 our borrowings were c. £15 million (June 2010: £122 million). As previously announced we arranged a new five year £300 million revolving credit facility during the first half of the year. The combination of our strong liquidity and these new facilities on improved terms will lead to lower finance costs in future periods, supporting further growth in profitability.

 

We continue to operate successfully in the current market and remain focussed on delivering further margin growth and free cash flow, supported by our strong high quality landbank.

 

We will announce our Half Year Results on Tuesday 23 August 2011 and provide further details at that time.

 

Mike Farley and Mike Killoran will host a conference call with analysts at 9.00 a.m. today. To participate please dial +44 (0)20 3059 5845. The password is 'Persimmon'.

 

 

For further information please contact:

 

Mike Farley, Group Chief Executive Edward Orlebar

Mike Killoran, Group Finance Director Charlotte McMullen

Persimmon Plc Marylene Guernier

Tel: +44 (0) 20 7920 2369 on the day M:Communications

Tel: +44 (0) 1904 642199 thereafter Tel: +44 (0) 20 7920 2369

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTRIMFTMBIMBTB
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.